VACTOSERTIB
Vactosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against activin receptor type-1B and TGF-beta receptor type-1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 3 | 4 | — | — | — | 5 |
| Adenocarcinoma | D000230 | — | — | 2 | 4 | — | — | — | 4 |
| Colorectal neoplasms | D015179 | — | — | 2 | 2 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 3 |
| Esophageal neoplasms | D004938 | — | C15 | 2 | 2 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | — | — | — | 2 |
| Desmoid tumors | D018222 | — | D48.11 | 1 | 2 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | — | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
| Syndrome | D013577 | — | — | 2 | — | — | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VACTOSERTIB |
| INN | vactosertib |
| Description | Vactosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against activin receptor type-1B and TGF-beta receptor type-1. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1 |
Identifiers
| PDB | — |
| CAS-ID | 1352608-82-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3260567 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 6T4O391P5Y (ChemIDplus, GSRS) |
Target
Agency Approved
ACVR1B
ACVR1B
TGFBR1
TGFBR1
Organism
Homo sapiens
Gene name
ACVR1B
Gene synonyms
ACVRLK4, ALK4
NCBI Gene ID
Protein name
activin receptor type-1B
Protein synonyms
activin A receptor, type IB, activin A receptor, type II-like kinase 4, Activin receptor type IB, Activin receptor-like kinase 4, ACTR-IB, ALK-4, Serine/threonine-protein kinase receptor R2, SKR2
Uniprot ID
Mouse ortholog
Acvr1b (11479)
activin receptor type-1B (Q61271)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 410 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use